Abstract
Rats treated with reserpine develop spontaneous orofacial dyskinesia that has features similar to tardive dyskinesia (TD) in humans. In contrast to TD, however, reserpine-induced oral dyskinesia develops rapidly reaching a maximal level within 3 days at a dose of 1 mg/kg per day. The present study examined whether rats administered lower doses of reserpine would develop the oral dyskinesia at a slower rate, similar to the protracted development of TD. Rats were administered 0, 0.01, 0.05, 0.1, or 1.0 mg/kg reserpine subcutaneously every other day for 100 days. Oral dyskinesia was measured by recording the incidence of tongue protrusions for 30 min on days 1, 4, 10, 20, 40, 60, and 100. The time course of the development of reserpine-induced oral dyskinesia varied dose-dependently. The response was evident within 4 days at 1 mg/kg, within 20 days at 0.1 mg/kg, within 60 days at 0.05 mg/kg, and was not evident at 0.01 mg/kg at any time during the 100 days of treatment. The protracted development of reserpine-induced oral dyskinesia at the lower doses is consistent with TD. Doses of reserpine that produced an increase in tongue protrusions also produced a 90–95% depletion of dopamine and an increase in the ratio of dopamine metabolites to dopamine in the caudate-putamen. The disruption of dopamine neurotransmission may be involved in development of the oral dyskinesia. Furthermore, it is suggested that the 1 mg/kg dose of reserpine may induce neurochemical changes similar to that produced by long-term neuroleptic treatment, but at an accelerated rate, thereby providing a new efficient model of TD.
Similar content being viewed by others
References
Baldessarini RJ, Cole JO, Davis JM, Simpson G, Tarsy D, Gardos G, Preskorn SH (1980) Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. Am J Psychiatry 137: 1163–1172
Brodkin J, Malyala A, Nash JF (1993) Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 45: 647–653
Cadet JL, Lohr JB, Jeste DV (1986) Free radicals and tardive dyskinesia. Trends Neurosci 9: 107–108
Callaway CW, Kuczenski R, Segal DS (1989) Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res 505: 83–90
Casey DE (1984) Tardive dyskinesia — animal models. Psychopharmacol Bull 20: 376–379
Commissiong JW (1985) Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem Pharmacol 34: 1127–1131
Ellison G, See R, Levin E, Kinney J (1987) Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology 92: 122–126
Fibiger HC, Lloyd KG (1984) Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 7: 462–464
Gardos G, Cole JO (1983) The prognosis of tardive dyskinesia. J Clin Psychiatry 44: 177–179
Gerlach J, Casey DE (1988) Tardive dyskinesia. Acta Psychiatr Scand 77: 369–378
German DC, McMillen BA, Sanghera MK, Saffer SI, Shore PA (1981) Effect of severe dopamine depletion on dopamine neuronal impulse flow and on tyrosine hydroxylase regulation. Brain Res Bull 6: 131–134
Gunne L, Barany S (1976) Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology 50: 237–240
Gunne LM, Häggström J-E (1983) Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology 81: 191–194
Gunne LM, Häggström J-E, Sjöquist B (1984) Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309: 347–349
Jenner P, Marsden CD (1986) Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends Neurosci: 259
Jenner P, Marsden CD (1988) Adaptive changes in brain dopamine function as a result of neuroleptic treatment. In: Jankovic J, Tolosa E (eds) Facial dyskinesias. Advances in Neurology, vol 49. Raven Press, New York
Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19: 303–315
Jeste DV, Wyatt RJ (1982) Therapeutic strategies against tardive dyskinesia. Arch Gen Psychiatry 39: 803–816
Joyce JN (1991) Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. Exp Neurol 113: 277–290
Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors 1959–1979. Arch Gen Psychiatry 39: 473–481
Kazamatsuri H, Chien CP, Cole JO (1972a) Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 27: 95–99
Kazamatsuri H, Chien CP, Cole JO (1972b) Treatment of tardive dyskinesia. II. Short term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry 27: 100–103
Klawans HL (1973) The pharmacology of tardive dyskinesias. Am J Psychiatry 130: 83–86
Klawans HL, Tanner CM, Barr A (1984) The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol 7: 153–159
Korf J, Gradijk L, Westerink, BHC (1976) Effects of electrical stimulation of the nigrostriatal pathway of the rat on dopamine metabolism. J Neurochem 26: 579–584
Lavielle S, Tassin JP, Thierry AM, Blanc G, Herve D, Barthelemy C, Glowinski J (1978) Blockade by benzodiazepines of the selective high increase in dopamine turnover induced by stress in mesocortical dopaminergic neurons of the rat. Brain Res 168: 585–594
Lohr JB (1991) Oxygen free radicals and neuropsychiatric illness. Arch Gen Psychiatry 48: 1097–1106
Marshall JF, O'Dell SJ, Weihmuller FB (1993) Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J Neural Transm 91: 241–254
Neisewander JL, Lucki I, McGonigle P (1991a) Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J Pharmacol Exp Ther 257: 850–860
Neisewander JL, Lucki I, McGonigle P (1991b) Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res 558: 27–35
O'Dell SJ, Weihmuller FB, Marshall JF (1991) Multiple methamphetamine injections induce marked increase in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res 564: 256–260
Robinson TE, Becker JB, Young AE, Akil H, Castañeda E (1987) The effects of footshock stress on regional brain dopamine metabolism and pituitary beta-endorphin release in rats previously sensitized to amphetamine. Neuropharmacology 26: 679–691
Roth RH, Murrin CL, Walters JR (1976) Central dopaminergic neurons: effects of alteration in impulse flow on the accumulation of dihydroxyphenylacetic acid. Eur J Pharmacol 36: 163–171
Scheel-Krüger J, Arnt J (1985) New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia. Psychopharmacology, Suppl. 2: 46–57
See RE (1991) Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci Lett 129: 265–268
See RE (1993) Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia. Neuropsychopharmacology 9: 101–109
See RE, Sant WW, Ellison GD (1987) Recording oral activity in rats reveals a long-lasting subsensitivity to haloperidol as a function of duration of previous haloperidol treatment. Pharmacol Biochem Behav 28: 175–178
See RE, Chapman MA, Murray CE, Aravagiri M (1992) Regional differences in chronic neuroleptic effects on extracellular dopamine activity. Brain Res Bull 29: 473–478
Shannak KS, Hornykiewicz O (1980) Brain monoamines in rhesus monkey during long-term neuroleptic administration. In: Cattabeni F (ed) Long-term effects of neuroleptics. Adv Biochem Psychopharmacol 24: 315–323
Shonecker M (1957) Ein eigentumliches Syndrom in eralen Bereich bei. Megaphen Applikation Nervenartz 28: 34
Smith JM, Baldessarini RJ (1980) Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 37: 1368–1373
Tank AW, Lewis EJ, Chikaraishi DM, Weiner N (1985) Elevation of RNA coding for tyrosine hydroxylase in rat adrenal gland by reserpine treatment and cold exposure. J Neurochem 45: 1030–1033
Uhrbrand L, Faurbye A (1960) Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine, and electroconvulsive therapy. Psychopharmacologia 1: 408–418
Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220: 530–532
Waddington JL, Youssef HA, Molloy AG, O'Boyle KM, Pugh MT (1985) Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: clinical and animal studies. J Clin Psychiatry 46: 29–33
Wessel TC, Joh TH (1992) Parallel upregulation of catecholamine-synthesizing enzymes in rat brain and adrenal gland: effects of reserpine and correlation with immediate early gene expression. Mol Brain Res 15: 349–360
Zigmond RE (1979) Tyrosine hydroxylase activity in noradrenergic neurons of the locus coeruleus after reserpine administration: sequential increase in cell bodies and nerve terminals. J Neurochem 32: 23–29
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neisewander, J.L., Castañeda, E. & Davis, D.A. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacology 116, 79–84 (1994). https://doi.org/10.1007/BF02244874
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244874